Vericel Corp Ord
$ 37.68
1.59%
26 Feb - close price
- Market Cap 1,875,791,000 USD
- Current Price $ 37.68
- High / Low $ 38.49 / 35.69
- Stock P/E 142.65
- Book Value 6.37
- EPS 0.26
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE 0.05 %
- 52 Week High 52.06
- 52 Week Low 29.24
About
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cell therapies for the sports medicine and severe burn care markets in the United States. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$55.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-26 | 2025-11-06 | 2025-07-31 | 2025-05-06 | 2025-02-26 | 2024-11-07 | 2024-08-01 | 2024-05-08 | 2024-02-29 | 2023-11-08 | 2023-08-02 | 2023-05-10 |
| Reported EPS | 0 | 0.1 | -0.01 | -0.23 | 0.38 | -0.02 | -0.1 | -0.08 | 0.26 | -0.08 | -0.11 | -0.16 |
| Estimated EPS | 0.3938 | -0.01 | -0.03 | -0.1533 | 0.34 | -0.05 | -0.08 | -0.11 | 0.17 | -0.12 | -0.15 | -0.15 |
| Surprise | -0.3938 | 0.11 | 0.02 | -0.0767 | 0.04 | 0.03 | -0.02 | 0.03 | 0.09 | 0.04 | 0.04 | -0.01 |
| Surprise Percentage | -100% | 1100% | 66.6667% | -50.0326% | 11.7647% | 60% | -25% | 27.2727% | 52.9412% | 33.3333% | 26.6667% | -6.6667% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.45 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VCEL
2026-02-18 17:57:31
CenterBook Partners LP significantly increased its stake in Vericel Corporation (NASDAQ:VCEL) by 171.1% in the third quarter, now owning 184,986 shares valued at approximately $5.82 million. Other institutional investors have also adjusted their holdings. Analysts have a "Moderate Buy" consensus rating for VCEL, with a target price of $57.50, against its recent trading price near $36.82.
2026-02-10 05:28:06
Vericel Corporation's stock (VCEL) recently hit $35.84, a high despite a 38% decline over the past year. Analysts maintain a "strong buy" consensus with price targets up to $62, and InvestingPro indicates the stock is undervalued with "GREAT" financial health. The company projects approximately $276 million in total revenue for 2025, showing 23% growth in Q4, and BTIG reiterated a Neutral rating following better-than-anticipated Q3 results.
2026-02-09 17:29:37
Vericel stock recently reached a high of $35.84, a notable recovery despite a 38% decline over the past year. Analysts maintain a "strong buy" consensus with price targets up to $62, and InvestingPro data indicates the stock is undervalued with "GREAT" financial health. The company also announced preliminary unaudited 2025 revenues of $276 million, showing strong growth in Q4.
2026-02-07 18:28:06
Thrivent Financial for Lutherans significantly reduced its stake in Vericel Corporation (NASDAQ:VCEL) by 36.8% in the third quarter, selling 116,509 shares. Despite this, Vericel reported a stronger-than-expected quarter with $0.10 EPS, beating previous consensus estimates. The stock, currently trading in the mid-$30s, holds a "Moderate Buy" consensus rating from analysts.
2026-02-06 18:29:05
Vericel Corp (NASDAQ:VCEL) is highlighted as an attractive investment due to its robust fundamental growth, including significant EPS and sales increases, and strong profitability in the biotechnology sector. Technically, the stock shows a potential breakout setup with a sideways trading pattern near support and minimal overhead resistance. This combination of strong fundamentals and a favorable technical formation suggests a future upward movement for the stock.
2026-02-05 07:29:20
Vericel Corporation is highlighted as a "Growth At a Reasonable Price" (GARP) investment due to its strong financial position, including a debt-free balance sheet and consistent revenue growth of around 15%. The company, specializing in advanced therapies for sports medicine and severe burn care, shows particular momentum with its MACI therapy. Investors are looking forward to the full-year and Q4 2025 financial results on February 26, 2026, for further insight into its profitability and future guidance.
